What Is DILIN?

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has established the Drug-Induced Liver Injury Network (DILIN) to collect and analyze cases of severe liver injury caused by prescription drugs, over-the-counter drugs, and alternative medicines, such as herbal products and supplements. Currently, DILIN is conducting 2 registry studies:

  • Retrospective Study, to establish a nationwide registry of people who have experienced liver injury within the past 10 years after using any of 7 specific drugs and one drug category (quinolone antibiotics).
  • Prospective Study, to establish a nationwide registry of people who have experienced liver injury within the past 6 months after using certain drugs or alternative products.
  • Causality Process and Web Application, The diagnosis of drug-induced liver injury relies on evidence linking the injury to a specific drug or agent. DILIN uses “expert opinion” to determine the degree of association between the implicated medication(s) and the liver injury. This process is identified as DiLiN Causality Case Adjudication which is the DiLiN project primary Endpoint. The DiLiN Causality Web Application is a system specifically developed for this purpose. This is a secure system which was developed by the DCRI IT group for the DILIN network based on an open source platform. The Causality Web Application’s mission is to streamline the previous process which will include more efficient case management and seamless system integration to existing DILIN databases. The DiLiN Causality Web Application is also providing greater consistency within the processes by applying business rules to user’s input.

map

Mt. Sinai RUCDR AEMC NIDDK/NIH Fisher DCRI UMHS nih/nci unc chapel hill Indiana University USC/UCLA

Interested in participating in this study?  Contact Us

The DILIN Network Members at the Steering Committee Meeting on April 28, 2014

Bolger Center: Potomac, Maryland

dilin_members

Front row, L to R: Averell Sherker (NIDDK), Jawad Ahmad (Mt Sinai), Huiman Barnhart (Duke), Robert Fontana (U Michigan), Paul Watkins (UNC), Jay Hoofnagle (NIDDK), David Kleiner (NCI), Jose Serrano (NIDDK)

Second Row, L to R: Hoss Rostami (Duke), Francesco Durazo (UCLA), Paul Hayashi (UNC), Raj Vuppalanchi (Indiana U), Leonard Seeff (FDA), Vic Navarro (Einstein), Naga Chalasani (Indiana U), Tom Urban (Duke)

Third Row, L to R: Susan Milstein (UCLA), Kristen Chesney(U Michigan), Nidia Rosado (Duke), Tracy Russell (UNC), Kathy Galan (Duke), Ynto de Boer (NIDDK), Carmel Scharenbroich (Duke), Andrew Stolz (USC)

Fourth Row, L to R: Varun Kesar (Mt Sinai), Don Rockey (MUSC), Hans Tillmann (Duke), Herb Bonkovsky (Carolinas), Manisha Verma (Einstein), Joe Odin (Mt Sinai), Sherrie Cummings (Indiana U), Jiezhun Gu (Duke)

The DILIN Network Investigators at the Steering Committee Meeting on April 28, 2014

Bolger Center: Potomac, Maryland

dilin_investigators

Front row, L to R: Averell Sherker (NIDDK), Jawad Ahmad (Mt Sinai), Huiman Barnhart (Duke), Robert Fontana (U Michigan), Paul Watkins (UNC), Joe Odin (Mt Sinai), Jose Serrano (NIDDK)

Second Row, L to R: Francesco Durazo (UCLA), Mark Avigan (FDA), Raj Vuppalanchi (Indiana U), Vic Navarro (Einstein), Naga Chalasani (Indiana U), Andrew Stolz (USC)

Third Row, L to R: Paul Hayashi (UNC), Herb Bonkovsky (Carolinas), Don Rockey (MUSC), Jay Hoofnagle (NIDDK)

Late Breaking News

Spike in Harm to Liver Is Tied to Dietary Aids

Fat Burning Supplement Linked to Liver Failure

Sanofi to Send Letter on Multaq Liver Failure Cases

FDA Drug Safety Communication: Severe liver injury associated with the use of dronedarone (marketed as Multaq)

Regulatory Science Update: FDA and International Serious Adverse Events Consortium Complete Third Data Release- Data focus on genetic basis of drug-induced liver injury and serious skin reaction

FDA Warns Consumers about Counterfeit Alli

FDA issues new warnings and precautions concerning diclofenac sodium, including Voltaren Gel

FDA Issues Early Communication about Ongoing Safety Review of Weight Loss Drug Orlistat